CorrigendumCorrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]
Under a Creative Commons license
open access
Cited by (0)
© 2020 The Author(s). Published by Elsevier Inc.